Cargando…

Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy

BACKGROUND: Chemotherapy‐related cognitive impairment (CRCI) is a common but easily overlooked condition that markedly affects the quality of life (QOL) of patients with breast cancer. The rs671 is a common gene polymorphism of aldehyde dehydrogenase 2 (ALDH2) in Asia that is involved in aldehyde me...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Senbang, Li, Wen, Liu, Shaochun, Cai, Yinlian, Zhang, Qianqian, Tang, Lingxue, Yu, Sheng, Jing, Yanyan, Yin, Xiangxiang, Cheng, Huaidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028021/
https://www.ncbi.nlm.nih.gov/pubmed/36200595
http://dx.doi.org/10.1002/cam4.5319
_version_ 1784909844546846720
author Yao, Senbang
Li, Wen
Liu, Shaochun
Cai, Yinlian
Zhang, Qianqian
Tang, Lingxue
Yu, Sheng
Jing, Yanyan
Yin, Xiangxiang
Cheng, Huaidong
author_facet Yao, Senbang
Li, Wen
Liu, Shaochun
Cai, Yinlian
Zhang, Qianqian
Tang, Lingxue
Yu, Sheng
Jing, Yanyan
Yin, Xiangxiang
Cheng, Huaidong
author_sort Yao, Senbang
collection PubMed
description BACKGROUND: Chemotherapy‐related cognitive impairment (CRCI) is a common but easily overlooked condition that markedly affects the quality of life (QOL) of patients with breast cancer. The rs671 is a common gene polymorphism of aldehyde dehydrogenase 2 (ALDH2) in Asia that is involved in aldehyde metabolism and may be closely related to CRCI. However, no study has yet summarised the association between ALDH2 and CRCI. METHODS: This study enrolled one hundred and twenty‐four patients diagnosed with breast cancer according to the pathology results, genotyped for ALDH2 single‐nucleotide polymorphisms (SNP) to explore these. The mini‐mental state exam (MMSE), verbal fluency test (VFT), and digit span test (DST) results were compared in these patients before and after chemotherapy (CT). RESULTS: We found that patients with ALDH2 gene genotypes of rs671_GG, rs886205_GG, rs4648328_CC, and rs4767944_TT polymorphisms were more likely to suffer from cognitive impairment during chemotherapy. A trend toward statistical significance was observed for rs671_GG of DST (z = 2.769, p = 0.006), VFT (t = 4.624, P<0.001); rs886205_GG of DST (z = 3.663, P<0.001); rs4648328_CC of DST (z = 2.850, p = 0.004), VFT (t = 3.477, p = 0.001); and rs4767944_TT of DST (z = 2.967, p = 0.003), VFT (t = 2.776, p = 0.008). The cognitive indicators of these patients significantly decreased after chemotherapy (p < 0.05). The difference in ALDH2 rs671 was most obvious. CONCLUSION: Our results showed what kinds of ALDH2 genotyped patients that are more likely to develop CRCI. In the future, it may be possible to infer the risk of CRCI by detecting the single‐nucleotide locus of ALDH2 that is conducive to strengthening clinical interventions for these patients and improving their QOL. More importantly, this study has important implications for Asian women with breast cancer as ALDH2 rs671 is a common polymorphism in Asians.
format Online
Article
Text
id pubmed-10028021
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100280212023-03-22 Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy Yao, Senbang Li, Wen Liu, Shaochun Cai, Yinlian Zhang, Qianqian Tang, Lingxue Yu, Sheng Jing, Yanyan Yin, Xiangxiang Cheng, Huaidong Cancer Med RESEARCH ARTICLES BACKGROUND: Chemotherapy‐related cognitive impairment (CRCI) is a common but easily overlooked condition that markedly affects the quality of life (QOL) of patients with breast cancer. The rs671 is a common gene polymorphism of aldehyde dehydrogenase 2 (ALDH2) in Asia that is involved in aldehyde metabolism and may be closely related to CRCI. However, no study has yet summarised the association between ALDH2 and CRCI. METHODS: This study enrolled one hundred and twenty‐four patients diagnosed with breast cancer according to the pathology results, genotyped for ALDH2 single‐nucleotide polymorphisms (SNP) to explore these. The mini‐mental state exam (MMSE), verbal fluency test (VFT), and digit span test (DST) results were compared in these patients before and after chemotherapy (CT). RESULTS: We found that patients with ALDH2 gene genotypes of rs671_GG, rs886205_GG, rs4648328_CC, and rs4767944_TT polymorphisms were more likely to suffer from cognitive impairment during chemotherapy. A trend toward statistical significance was observed for rs671_GG of DST (z = 2.769, p = 0.006), VFT (t = 4.624, P<0.001); rs886205_GG of DST (z = 3.663, P<0.001); rs4648328_CC of DST (z = 2.850, p = 0.004), VFT (t = 3.477, p = 0.001); and rs4767944_TT of DST (z = 2.967, p = 0.003), VFT (t = 2.776, p = 0.008). The cognitive indicators of these patients significantly decreased after chemotherapy (p < 0.05). The difference in ALDH2 rs671 was most obvious. CONCLUSION: Our results showed what kinds of ALDH2 genotyped patients that are more likely to develop CRCI. In the future, it may be possible to infer the risk of CRCI by detecting the single‐nucleotide locus of ALDH2 that is conducive to strengthening clinical interventions for these patients and improving their QOL. More importantly, this study has important implications for Asian women with breast cancer as ALDH2 rs671 is a common polymorphism in Asians. John Wiley and Sons Inc. 2022-10-06 /pmc/articles/PMC10028021/ /pubmed/36200595 http://dx.doi.org/10.1002/cam4.5319 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Yao, Senbang
Li, Wen
Liu, Shaochun
Cai, Yinlian
Zhang, Qianqian
Tang, Lingxue
Yu, Sheng
Jing, Yanyan
Yin, Xiangxiang
Cheng, Huaidong
Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy
title Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy
title_full Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy
title_fullStr Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy
title_full_unstemmed Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy
title_short Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy
title_sort aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028021/
https://www.ncbi.nlm.nih.gov/pubmed/36200595
http://dx.doi.org/10.1002/cam4.5319
work_keys_str_mv AT yaosenbang aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy
AT liwen aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy
AT liushaochun aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy
AT caiyinlian aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy
AT zhangqianqian aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy
AT tanglingxue aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy
AT yusheng aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy
AT jingyanyan aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy
AT yinxiangxiang aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy
AT chenghuaidong aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy